BioLineRx (NASDAQ:BLRX) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of BioLineRx (NASDAQ:BLRX) in a research note issued to investors on Saturday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright cut their target price on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating for the company in a research note on Monday, November 25th.

BioLineRx Stock Performance

NASDAQ BLRX opened at $0.14 on Friday. The firm has a 50-day moving average of $0.30 and a 200-day moving average of $0.51. The company has a debt-to-equity ratio of 2.11, a quick ratio of 1.37 and a current ratio of 1.52. The stock has a market cap of $11.42 million, a PE ratio of -0.65 and a beta of 1.46. BioLineRx has a 52-week low of $0.14 and a 52-week high of $1.52.

Institutional Trading of BioLineRx

A number of hedge funds have recently modified their holdings of BLRX. PVG Asset Management Corp bought a new position in BioLineRx during the second quarter worth about $70,000. Atria Investments Inc increased its position in BioLineRx by 27.9% during the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 29,193 shares during the period. Finally, CVI Holdings LLC bought a new position in BioLineRx during the second quarter worth about $462,000. Institutional investors and hedge funds own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.